Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.72 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | CA1 | P00915 | 7/20 | 0.43 |
| ▸ | CA9 | Q16790 | 7/20 | 0.43 |
| ▸ | CA12 | O43570 | 6/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.43 |
| ▸ | CA7 | P43166 | 4/20 | 0.43 |
| ▸ | CA3 | P07451 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 3/20 | 0.43 |
| ▸ | CA6 | P23280 | 3/20 | 0.43 |
| ▸ | CA5A | P35218 | 3/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1164097 | 1.00 | PRMT5 (0.72) | PRMT5WDR77PKMALDH1A1LMNA | |
| SCHEMBL2967442 | 1.00 | PRMT5 (0.72) | PRMT5WDR77PKMALDH1A1LMNA | |
| SCHEMBL30301224 | 0.84 | PRMT5 (1.00) | PRMT5WDR77ALDH1A1LMNAGAA | |
| SCHEMBL336605 | 0.84 | PRMT5 (1.00) | PRMT5WDR77ALDH1A1LMNAGAA | |
| SCHEMBL336603 | 0.84 | PRMT5 (1.00) | PRMT5WDR77ALDH1A1LMNAGAA | |
| SCHEMBL29481767 | 0.84 | PRMT5 (1.00) | PRMT5WDR77ALDH1A1LMNAGAA | |
| SCHEMBL449928 | 0.84 | PRMT5 (1.00) | PRMT5WDR77ALDH1A1LMNAGAA | |
| SCHEMBL29476299 | 0.84 | PRMT5 (1.00) | PRMT5WDR77ALDH1A1LMNAGAA | |
| SCHEMBL9303799 | 0.83 | PRMT5 (0.53) | PRMT5WDR77PKMALDH1A1CA2 | |
| SCHEMBL7470093 | 0.83 | PRMT5 (0.67) | PRMT5WDR77PKMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106582334-A | Composite reverse osmosis membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2017-04-26 | — | — | CN | claimed |
| US-20140275576-A1 | PROCESS FOR THE PREPARATION OF (2,3-DIHYDRO-BENZO[B][1,4]DIOXIN-2-YL) METHANOL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | claimed |
| US-12303474-B2 | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | ACTIMED THERAPEUTICS LIMITED (GB) | 2025-05-20 | — | — | US | disclosed |
| US-20240325322-A1 | S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | ACTIMED THERAPEUTICS LTD (GB) | 2024-10-03 | — | — | US | disclosed |
| US-11938102-B2 | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | ACTIMED THERAPEUTICS LIMITED (GB) | 2024-03-26 | — | — | US | disclosed |
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-12-28 | — | — | US | disclosed |
| CN-117242073-A | PRMT5 inhibitors and uses thereof | 海思科医药集团股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2022206964-A1 | PRMT5 INHIBITOR AND USE THEREOF | 海思科医药集团股份有限公司 | 2022-10-06 | — | — | WO | disclosed |
| US-11433036-B2 | Oxprenolol compositions for treating cancer | ACTIMED THERAPEUTICS LIMITED (GB) | 2022-09-06 | — | — | US | disclosed |
| CN-106582334-A | Composite reverse osmosis membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2017-04-26 | — | — | CN | disclosed |
| WO-2014140220-A1 | PROCESS FOR THE PREPARATION OF (2,3-DIHYDRO-BENZO[B][1,4]DIOXIN-2-YL) METHANOL DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275576-A1 | PROCESS FOR THE PREPARATION OF (2,3-DIHYDRO-BENZO[B][1,4]DIOXIN-2-YL) METHANOL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| CN-1984906-A | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC (JP) | 2007-06-20 | — | — | CN | disclosed |
| CN-1139586-C | Process for stereoselective preparation of hetero-bicyclic alcohol enantiomer | �ŷƶ����ʿ�������˾ | 2004-02-25 | — | — | CN | disclosed |
| CN-1160714-A | Process for stereoselective preparation of hetero-bicyclic alcohol enantiomer | DUPHAR INT RES (NL) | 1997-10-01 | — | — | CN | disclosed |
| EP-0512020-A1 | PROCESS FOR PREPARING HOMOCHIRAL AMINES AND PROCESS FOR PREPARING INTERMEDIATES FOR THE PREPARATION THEREOF | Nobel Chemicals AB (SE) | 1992-11-11 | — | — | EP | disclosed |
| WO-1991010642-A1 | PROCESS FOR PREPARING HOMOCHIRAL AMINES AND PROCESS FOR PREPARING INTERMEDIATES FOR THE PREPARATION THEREOF, AND THE INTERMEDIATES PREPARED IN ACCORDANCE WITH THIS PROCESS | NOBEL CHEMICALS AB (SE) | 1991-07-25 | — | — | WO | disclosed |
| US-4877892-A | Chiral glycidyl azides as synthetic intermediates to optically active compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12303474-B2 | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | SMN1; SMN2, CPT1B, ADRB1 | PRMT5 2446/4885WDR77 755/4885PKM 3652/4885 |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | PRMT5 79/4885WDR77 315/4885PKM 1173/4885 |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | PRMT5 78/4885WDR77 311/4885PKM 1154/4885 |
| US-11433036-B2 | Oxprenolol compositions for treating cancer | ADRB1, ADRB2, CPT1B | PRMT5 3236/4885WDR77 658/4885PKM 1328/4885 |
| US-11938102-B2 | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | SMN1; SMN2, CPT1B, ADRB1 | PRMT5 2446/4885WDR77 755/4885PKM 3652/4885 |
| US-20240325322-A1 | S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, CPT1B, ADRB1 | PRMT5 2446/4885WDR77 755/4885PKM 3652/4885 |
| US-20140275576-A1 | PROCESS FOR THE PREPARATION OF (2,3-DIHYDRO-BENZO[B][1,4]DIOXIN-2-YL) METHANOL DERIVATIVES | CYP1B1, CYP1A1, CYP4B1 | PRMT5 4038/4885WDR77 2902/4885PKM 2680/4885 |
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | PRMT5 79/4885WDR77 315/4885PKM 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.